<DOC>
	<DOCNO>NCT02248233</DOCNO>
	<brief_summary>Massive cerebral infarction ischemic stroke cause complete blockage internal carotid artery , middle cerebral artery , cortical branch . The widespread infarction , pathological severity high fatality rate associate massive cerebral infarction pose major threat affect patient . However , lack unified diagnostic criterion . Many researcher use Adams ' classification , massive cerebral infarction diagnose follow criterion meet : infarct size &gt; 13 cm2 ; major brain-feeding artery involve ; focal site affect two cerebral lobe ; infarct diameter line ≥ 3 cm internal capsule striatum . Prolonged cerebral ischemia/reperfusion induce complex secondary change brain tissue , use neuroprotective agent important . Remarkable progress make last decade understand protective effect calcium antagonists cerebral ischemia . In particular , liposoluble dihydropyridine Ca2+ antagonist nimodipine selectively act cerebral vessel neuron protect ischemic brain tissue , provide new way treat ischemic cerebrovascular disease . Preclinical clinical test show nimodipine protective effect ischemic brain tissue , indicate patient take drug soon possible . However , report double-blind , randomize , control clinical trial address administration nimodipine via intravenous drip within time window successful treatment acute massive cerebral infarction .</brief_summary>
	<brief_title>Nimodipine Treating Acute Massive Cerebral Infarction</brief_title>
	<detailed_description>In clinic , physician reluctant use thrombolysis , Defibrase anticoagulation therapy severity symptom , poor prognosis , risk hemorrhage high fatality rate occur acute massive cerebral infarction . Nimodipine , selective Ca2+ antagonist , highly liposoluble , effectively cross blood-brain barrier , selectively act intracranial blood vessel , accept neuroprotective agent apply clinic . The aim present study perform double-blind , randomize control trial clinical efficacy safety nimodipine administer intravenous drip early stage acute massive cerebral infarction . Patients receive nimodipine within 3 day infarction onset . We closely monitor follow : ( 1 ) Blood pressure heart rate patient treatment , since nimodipine contraindicate patient hypotension low heart rate . Where blood pressure ≥ 100/80 mmHg heart rate ≥ 60 BPM , nimodipine administer . ( 2 ) Speed infusion . This fast ; suggest 1-2 drop per minute initially , increase gradually drop systolic pressure exceed 10 mmHg . The average drip speed 6-8 drops/minute , fast drip speed 10 drops/minute . ( 3 ) During infusion , physician monitor adverse reaction headache , dizziness , flush sweating . If occur , infusion speed must reduce . If patient remain uncomfortable , nimodipine withdrawn . ( 4 ) Liver kidney function monitor throughout nimodipine administration . Although nimodipine relatively safe , still risk adverse effect , cardiovascular system reaction ( blood pressure decrease , bradycardia , angina , atrioventricular block ) , headache , dizziness , edema , liver kidney dysfunction . It necessary determine optimal therapeutic time window dose nimodipine multi-center , large-scale clinical trial .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Nimodipine</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>First onset age ≤ 80 year , severe medical complication ; Clear consciousness mild disturbance consciousness ; paralysis upper low extremity one side grade 03 muscle strength paralyze limb ; CT reveal early massive cerebral infarction ( without cerebral hemorrhage old infarction ) ; Blood pressure within , high , normal range . Clinical manifestation noticeably improve treatment ; Disorders consciousness , manifest severe lethargy coma ; Mild neurological deficit , pure sensory disturbance , ataxia , dysarthria , hemiparesis ; Severe hypotension ( systolic pressure &lt; 90 mmHg , diastolic pressure &lt; 60 mmHg ) ; Heart rate &lt; 60 BPM ; sinus bradycardia ; Severe heart , brain kidney dysfunction , malignant tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>nimodipine</keyword>
	<keyword>acute massive cerebral infarction</keyword>
	<keyword>Cerebral Infarction</keyword>
	<keyword>optimal therapeutic time window</keyword>
	<keyword>optimal dose</keyword>
	<keyword>multi-center</keyword>
</DOC>